These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1100213)

  • 21. Evaluation of alpha methyl dopa and alpha methyl dopa hydrazine with L-dopa therapy.
    Mones RJ
    N Y State J Med; 1974 Jan; 74(1):47-51. PubMed ID: 4591989
    [No Abstract]   [Full Text] [Related]  

  • 22. [Carbiodopa-levodopa therapy (Sinemet) in the treatment of parkinsonian patients. Results of 4 years of treatment].
    Martínez-Lage JM; Burguera JA; Deldago G; Zubieta JL
    Arch Neurobiol (Madr); 1978; 41(1):3-18. PubMed ID: 697513
    [No Abstract]   [Full Text] [Related]  

  • 23. Amantadine and a fixed combination of levodopa and carbidopa in the treatment of Parkinson's disease.
    Savery F
    Dis Nerv Syst; 1977 Aug; 38(8):605-8. PubMed ID: 328244
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The long-term effects of combining carbidopa with levodopa for Parkinson's disease.
    Lee MC; Lippert DM; Loewenson RB; Tolosa ES; Resch JA; Martin WE
    Trans Am Neurol Assoc; 1976; 101():262-4. PubMed ID: 829295
    [No Abstract]   [Full Text] [Related]  

  • 25. Increased dosage of carbidopa in patients with Parkinson's disease receiving low doses of levodopa. A pilot study.
    Hoehn MM
    Arch Neurol; 1980 Mar; 37(3):146-9. PubMed ID: 7356419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bromocriptine in the treatment of Parkinson's disease: a double-blind study against L-dopa/carbidopa.
    Gawel M; Riopelle R; Libman I; Bouchard S
    Adv Neurol; 1987; 45():535-8. PubMed ID: 3548263
    [No Abstract]   [Full Text] [Related]  

  • 27. Parkinsonism-dementia of Guam: treatment with levodopa and L-alpha-methyldopahydrazine.
    Holden EM; Brody JA; Chase TN
    Neurology; 1974 Mar; 24(3):263-5. PubMed ID: 4855953
    [No Abstract]   [Full Text] [Related]  

  • 28. L-dopa and carbidopa (sinemet) in the management of parkinsonism.
    Critchley E
    Postgrad Med J; 1975 Sep; 51(599):619-21. PubMed ID: 1105500
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined use of benserazide and carbidopa in Parkinson's disease.
    Lieberman AN; Goldstein M; Gopinathan G; Neophytides A; Hiesiger E; Walker R; Nelson J
    Neurology; 1984 Feb; 34(2):227-9. PubMed ID: 6538015
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Controlled study on the possibilities of L-dopa in the residual extrapyramidal syndrome caused by neuroleptics].
    Gutiérrez M; Alpert M; Guimón J; Friedhoff AJ; Veramendi V
    Actas Luso Esp Neurol Psiquiatr Cienc Afines; 1979; 7(3):181-8. PubMed ID: 382762
    [No Abstract]   [Full Text] [Related]  

  • 31. Metoclopramide and pimozide in Parkinson's disease and levodopa-induced dyskinesias.
    Tarsy D; Parkes JD; Marsden CD
    J Neurol Neurosurg Psychiatry; 1975 Apr; 38(4):331-5. PubMed ID: 1095689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of apomorphine and apomorphine-L-dopa-carbidopa on alcohol post-intoxication symptoms.
    Wadstein J; Ohlin H; Stenberg P
    Drug Alcohol Depend; 1978 Jul; 3(4):281-7. PubMed ID: 357128
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of selegiline plus L-dopa-carbidopa versus L-dopa-carbidopa alone in the treatment of Parkinson's disease.
    Brannan T; Yahr MD
    Ann Neurol; 1995 Jan; 37(1):95-8. PubMed ID: 7818264
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison between results achieved by administering L-dopa and Sinemet in parkinsonism in the light of our records].
    Szulc-Kuberska J; Niewodniczy A; Poźniak-Patewics E; Wolczyk-Orzechowska M
    Neurol Neurochir Pol; 1975; 9(5):611-5. PubMed ID: 1186952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F; Mentasti M; Riederer P; Birkmayer W
    Wien Klin Wochenschr; 1979 May; 91(10):332-7. PubMed ID: 452602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Parkinson's disease treated with Sinemet or Madopar. A controlled multicenter trial.
    Pakkenberg H; Birket-Smith E; Dupont E; Hansen E; Mikkelsen B; Presthus J; Rautakorpi I; Riman E; Rinne UK
    Acta Neurol Scand; 1976 May; 53(5):376-85. PubMed ID: 1266576
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolactin response to acute administration of different L-dopa plus decarboxylase inhibitors in Parkinson's disease.
    Ruggieri S; Falaschi P; Baldassarre M; D'Urso R; De Giorgio G; Rocco A; Agnoli A
    Neuropsychobiology; 1982; 8(2):102-8. PubMed ID: 7070643
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The clinical experience with the decarboxylase-blocked levodopa (Nacom) in the Parkinsonism patients].
    Völler GW; Deze J
    ZFA (Stuttgart); 1976 Mar; 52(7):380-8. PubMed ID: 773025
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.